<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain><z:e sem="disease" ids="C0024408" disease_type="Disease or Syndrome" abbrv="MJD|SCA3">Machado-Joseph disease</z:e> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MJD</z:e>), also known as Spinocerebellar <z:hpo ids='HP_0001251'>Ataxia</z:hpo> type 3, is an inherited dominant autosomal <z:e sem="disease" ids="C0524851" disease_type="Disease or Syndrome" abbrv="">neurodegenerative disorder</z:e> </plain></SENT>
<SENT sid="1" pm="."><plain>An expansion of <z:chebi fb="1" ids="16040">Cytosine</z:chebi>-<z:chebi fb="1" ids="16708">Adenine</z:chebi>-<z:chebi fb="1" ids="16235">Guanine</z:chebi> (CAG) repeats in the ATXN3 gene is translated as an expanded polyglutamine domain in the disease protein, ataxin-3 </plain></SENT>
<SENT sid="2" pm="."><plain>Selective <z:hpo ids='HP_0002180'>neurodegeneration</z:hpo> in <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MJD</z:e> is evident in several subcortical brain regions including the cerebellum </plain></SENT>
<SENT sid="3" pm="."><plain><z:hpo ids='HP_0001427'>Mitochondrial</z:hpo> dysfunction has been proposed as a mechanism of <z:hpo ids='HP_0002180'>neurodegeneration</z:hpo> in polyglutamine disorders </plain></SENT>
<SENT sid="4" pm="."><plain>In this study, we used different cell models and transgenic mice to assess the importance of mitochondria on cytotoxicity observed in <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MJD</z:e> </plain></SENT>
<SENT sid="5" pm="."><plain>Transiently transfected HEK cell lines with expanded (Q84) ataxin-3 exhibited a higher susceptibility to <z:chebi fb="0" ids="16348">3-nitropropionic acid</z:chebi> (3-NP), an irreversible inhibitor of <z:hpo ids='HP_0001427'>mitochondrial</z:hpo> complex II </plain></SENT>
<SENT sid="6" pm="."><plain>Increased susceptibility to 3-NP was also detected in stably transfected PC6-3 cells that inducibly express expanded (Q108) ataxin-3 in a <z:chebi fb="9" ids="27902">tetracycline</z:chebi>-regulated manner </plain></SENT>
<SENT sid="7" pm="."><plain>Moreover, cerebellar granule cells from <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MJD</z:e> transgenic mice were more sensitive to 3-NP inhibition than <z:mp ids='MP_0002169'>wild-type</z:mp> cerebellar neurons </plain></SENT>
<SENT sid="8" pm="."><plain>PC6-3 (Q108) cells differentiated into a neuronal-like phenotype with nerve growth factor (NGF) exhibited a significant decrease in <z:hpo ids='HP_0001427'>mitochondrial</z:hpo> complex II activity </plain></SENT>
<SENT sid="9" pm="."><plain>Mitochondria from <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MJD</z:e> transgenic mouse model and lymphoblast cell lines derived from <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MJD</z:e> patients also showed a trend toward reduced complex II activity </plain></SENT>
<SENT sid="10" pm="."><plain>Our results suggest that <z:hpo ids='HP_0001427'>mitochondrial</z:hpo> complex II activity is moderately compromised in <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MJD</z:e>, which may designate a common feature in polyglutamine toxicity </plain></SENT>
</text></document>